A5091263378- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Neuroendocrine Tumor Research Advances
- BIM and Construction Integration
- Inflammatory Biomarkers in Disease Prognosis
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Lung Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- 3D Surveying and Cultural Heritage
- Occupational and environmental lung diseases
- Cancer therapeutics and mechanisms
- Ferroptosis and cancer prognosis
- Augmented Reality Applications
- Innovations in Concrete and Construction Materials
- Esophageal Cancer Research and Treatment
- Cancer, Lipids, and Metabolism
- Architecture and Computational Design
- Economic and Financial Impacts of Cancer
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Respiratory Support and Mechanisms
Ospedale dell' Angelo
2021-2025
University of Padua
2013-2024
Istituto Oncologico Veneto
2017-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2017-2024
Weatherford College
2024
Associazione Italiana Di Oncologia Medica
2021-2022
Ospedale Civile di Venezia
2022
Peking Union Medical College Hospital
2022
Chinese Academy of Medical Sciences & Peking Union Medical College
2022
University of Minho
2020
Abstract Background Immune-checkpoint inhibitors (ICIs) are now standard of care for advanced non-small cell lung cancer (NSCLC). Unfortunately, many patients experience immune-related adverse events (irAEs), which usually mild and reversible, but they require timely management may be life threatening. No predictive markers irAEs available. Materials Methods The neutrophil-to-lymphocyte ratio (NLR) platelet-to-lymphocyte (PLR) were evaluated in with NSCLC consecutively treated ICIs....
Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients at least three metastatic sites, brain metastases, and symptoms diagnosis seem to have worse prognosis.Osimertinib became the standard treatment for untreated cancer (aNSCLC) following results reported phase...
Characterization of tumor-related genetic alterations is promising for the screening new predictive markers in non-small cell lung cancer (NSCLC). Aim study was to evaluate prognostic and role most frequent tumor-associated detected plasma before starting immune checkpoint inhibitors (ICIs).Between January 2017 October 2019, advanced NSCLC patients were prospectively screened with next-generation sequencing (NGS) while included two trials: VISION (NCT02864992), using Guardant360® test, MAGIC...
Liquid biopsy has the potential to monitor biological effects of treatment. KRAS represents most commonly mutated oncogene in Caucasian non-small-cell lung cancer (NSCLC). The aim this study was explore association dynamic plasma genotyping with outcome advanced NSCLC patients.Advanced patients were prospectively enrolled. Plasma samples collected at baseline (T1), after 3 or 4 weeks, according treatment schedule (T2) and first radiological restaging (T3). Patients carrying mutation tissue...
Background Recent clinical trials demonstrated longer survival in extended small cell lung cancer (SCLC) patients treated with immunotherapy addition to chemotherapy. However, the magnitude of benefit is modest and impact real-world setting has be fully established. Methods We collected data radiological imaging affected by or relapsing SCLC consecutively according practice between 2016 2023. As primary end-point, we compared pre-defined outcome indicators before after introduction...
For selected early stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio (NLR), and platelet-lymphocyte (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was investigate the prognostic value NLR PLR Caucasian patients resected SCLC, as potential tool select for multimodal treatment surgery.Consecutive evaluated at three centers...
Purpose Small-cell lung cancer (SCLC) is an aggressive disease with a dismal prognosis. The addition of immune checkpoints inhibitors to standard platinum-based chemotherapy in first-line setting achieves durable benefit only patient subgroup. Thus, the identification predictive biomarkers urgent unmet medical need. Experimental design Tumor samples from naive extensive-stage (ES) SCLC patients receiving atezolizumab plus carboplatin–etoposide were analyzed by gene expression profiling and...
Targeted agents have improved the outcome of a subset non-small cell lung cancer (NSCLC). Molecular profiling by next-generation sequencing (NGS) allows screening for multiple genetic alterations both in tissue and plasma, but limited data are available concerning its feasibility impact real-world clinical practice.
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionised treatment of advanced non-small cell lung cancer (aNSCLC), but a proportion patients had no clinical benefit and even experienced detrimental effects. This study aims to characterise experiencing hyperprogression (HPD) early death (ED) by longitudinal liquid biopsy. Methods aNSCLC receiving ICIs were prospectively enrolled. Plasma was collected at baseline (T1) after 3/4 weeks treatment, according the schedule (T2)....
High heterogeneity in clinical benefit characterizes the use of immune checkpoint inhibitors (ICIs) non-small cell lung cancer (NSCLC). We prospectively enrolled 113 advanced NSCLC patients treated with ICIs and performed liquid biopsy at time ICI start (T1), after 3 weeks (T2) radiological evaluation (T3). Molecular variables were associated outcome endpoints: cfDNA quantification, its dynamic change (∆T2-T1), variant allele frequency (VAF) gene highest detected baseline NGS (maxVAF)...
Background/Objectives: EBUS-TBNA is a safe and minimally invasive procedure to evaluate hilar mediastinal lymph nodes (LNs). The Franseen needle provides transbronchial biopsy (TBNB). Various sizes are available. In the literature, diagnostic yield (DY) sample adequacy (SA) between still being debated. Methods: total, 88 patients with lymphadenopathy were consecutively enrolled from June December 2021. Chest CT PET/CT scans performed. Dimension at imaging EBUS standardized uptake value (SUV)...
The role of Transesophageal bronchoscopic ultrasound-guided fine needle aspiration (EUS-B-FNA) in the diagnosis malignant pulmonary lesions adjacent to esophagus is a well-known procedure with high diagnostic yield. Moreover, it indicated for lung cancer staging. Franseen tip crown-cut that allow obtain tissue cores and provide huge amount pathologist's evaluation, moving from (FNA) biopsy (FNB). Few data about EUS-B-FNB are available Literature. Between May 2022 June 2024, 33 patients...
The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients.
Tyrosine-kinase inhibitors (TKIs) represent the best treatment for advanced non-small cell lung cancer (NSCLC) with common exon 19 deletion or 21 epidermal growth factor receptor mutation (EGFRm). This is an observational study investigating epidemiology, clinical features and outcome of NSCLC cases harbouring rare/complex EGFRm.Among 764 non-squamous known EGFRm status, 26(3.4%) harboured EGFRm. Patients receiving first-line TKIs (N = 17) achieved median Progression Free Survival (PFS)...